{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T18:09:35Z","timestamp":1767204575708,"version":"build-2238731810"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Chronic lymphocytic leukaemia (CLL) is a lymphoproliferative disorder of abnormal B-lymphocytes. Due to immune deregulation and therapy-related factors, CLL individuals face increased infection risks, making vaccination a priority. Although COVID-19 is no longer a global emergency, understanding vaccine responses in this vulnerable population, especially those undergoing active cancer treatments, remains critical for broader infectious disease prevention strategies. We have characterized the humoral and cellular immune response of SARS-CoV-2 vaccination elicited by CLL individuals under standard-of-care treatment and watch and wait (W&amp;amp;W) strategy compared with healthy subjects who received a three-dose regimen six months ago. Seroconversion rates varied between 81.8% and 71.4% in individuals under W&amp;amp;W and dropped to 28.6%-22.2% in those under treatment, with antibody titres and neutralizing activity following the same pattern, highlighting the impact of active therapies on vaccine immunogenicity. Analysis of B-cell dynamics revealed that individuals under W&amp;amp;W maintained the highest levels of total B cells (CD19+) throughout the study (up to 3.5-fold higher than healthy donors, p&amp;lt;0.0001). Basal na\u00efve B cells were markedly reduced across CLL groups (up to 4.3-fold lower in treated\n                    <jats:italic>vs<\/jats:italic>\n                    . W&amp;amp;W, p&amp;lt;0.0001), while memory subsets expanded over time, particularly in the W&amp;amp;W cohort after booster vaccination. Additionally, we found that the actively treated CLL group exhibited higher levels of cytotoxic cells (including CD8+ T cells and NK cells) when compared to the W&amp;amp;W or the healthy population groups. However, none of these cell populations demonstrated an increased activation capacity. Moreover, the direct cytotoxic capacity of peripheral blood mononuclear cells (PBMCs) from CLL persons was also more efficient in the W&amp;amp;W group. Through our comprehensive characterization of both humoral and cellular immune responses in CLL individuals, this study provides insight into the complex immunological landscape following SARS-CoV-2 vaccination. Our detailed analysis supports the current vaccination strategy against SARS-CoV-2 for CLL patients, confirming its effectiveness and underscoring the importance of close monitoring and representing a significant advancement in our understanding of immune responses in hematological malignancies.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2025.1571680","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T01:22:51Z","timestamp":1749172971000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Immune response dynamics of SARS-CoV-2 vaccination in chronic lymphocytic leukemia individuals: a descriptive analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Clara","family":"S\u00e1nchez-Men\u00e9ndez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Zurdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Corona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Mateos de la Morenas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Rodr\u00edguez-Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guiomar","family":"Casado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"Garc\u00eda-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayte","family":"P\u00e9rez-Olmeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Dom\u00ednguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Ar\u00e1nzazu","family":"Murciano-Ant\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"L\u00f3pez-Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valent\u00edn","family":"Garc\u00eda-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayte","family":"Coiras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Montserrat","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"16096","DOI":"10.1038\/nrdp.2016.96","article-title":"Chronic lymphocytic leukaemia","volume":"3","author":"Kipps","year":"2017","journal-title":"Nat Rev Dis Primer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2009.12.004","article-title":"Infectious complications of chronic lymphocytic leukaemia: pathogenesis, spectrum of infection, preventive approaches","volume":"23","author":"Morrison","year":"2010","journal-title":"Best Pract Res Clin Haematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.23750\/abm.v91i1.9397","article-title":"WHO declares COVID-19 a pandemic","volume":"91","author":"Cucinotta","year":"2020","journal-title":"Acta Bio Med Atenei Parm"},{"key":"B5","unstructured":"WHO Coronavirus (COVID-19) Dashboard"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0959-x","article-title":"COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus","volume":"34","author":"Scarf\u00f2","year":"2020","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006965","article-title":"Outcomes of COVID-19 in patients with CLL: a multicenter international experience","volume":"136","author":"Mato","year":"2020","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000811","article-title":"COVID-19 vaccination response and its practical application in patients with chronic lymphocytic leukemia","volume":"7","author":"Shadman","year":"2023","journal-title":"HemaSphere"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.v111.2","article-title":"Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological Malignancies","volume":"111","author":"Heftdal","year":"2023","journal-title":"Eur J Haematol"},{"key":"B10","article-title":"Posicionamiento_SEOM_Vacunas_para_oncologos.pdf","year":"2022"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.280163","article-title":"Antibody response after vaccination against SARS-CoV-2 in adults with hematological Malignancies: a systematic review and meta-analysis","volume":"107","author":"Gagelmann","year":"2022","journal-title":"Haematologica"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26459","article-title":"COVID-19 vaccine response in patients with hematologic Malignancy: A systematic review and meta-analysis","volume":"97","author":"Gong","year":"2022","journal-title":"Am J Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006215","article-title":"Humoral response to mRNA anti-COVID-19 vaccines BNT162b2 and mRNA-1273 in patients with chronic lymphocytic leukemia","volume":"6","author":"Bagacean","year":"2022","journal-title":"Blood Adv"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13045-021-01219-7","article-title":"Impaired neutralization of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia","volume":"15","author":"Parry","year":"2022","journal-title":"J Hematol Oncol.J Hematol Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26951","article-title":"Kinetics of cellular and humoral immunogenicity and effectiveness of SARS-CoV -2 booster vaccination in hematologic neoplasms","volume":"98","author":"Jim\u00e9nez","year":"2023","journal-title":"Am J Hematol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01583-20","article-title":"A founder effect led early SARS-coV-2 transmission in Spain","volume":"95","author":"D\u00edez-Fuertes","year":"2021","journal-title":"J Virol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.20770","article-title":"A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1","volume":"79","author":"Garcia-Perez","year":"2007","journal-title":"J Med Virol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1038\/s41467-020-15562-9","article-title":"Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV","volume":"11","author":"Ou","year":"2020","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5537","DOI":"10.3390\/cancers14225537","article-title":"Strong Humoral but Not Cellular Immune Responses against SARS-CoV-2 in Individuals with Oncohematological Disease Who Were Treated with Rituximab before Receiving a Vaccine Booster","volume":"14","author":"Torres","year":"2022","journal-title":"Cancers"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-285528","article-title":"B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy","volume":"116","author":"Moir","year":"2010","journal-title":"Blood"},{"key":"B21","unstructured":""},{"key":"B22","volume-title":"COVID-19 medicines","year":"2023"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad121","article-title":"Humoral immunity after COVID-19 vaccination in chronic lymphocytic leukemia and other indolent lymphomas: A single-center observational study","volume":"121","author":"Doukas","year":"2023","journal-title":"Oncologist"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.31662\/jmaj.2023-0171","article-title":"Efficacy of COVID-19 vaccines in patients with hematological Malignancy compared to healthy controls: A systematic review and meta-analysis","volume":"7","author":"Das Barshan","year":"2024","journal-title":"JMA J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/hon.v39.5","article-title":"COVID-19 vaccination: Evaluation of risk for protection failure in chronic lymphocytic leukemia patients","volume":"39","author":"Del Poeta","year":"2021","journal-title":"Hematol Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01380-5","article-title":"Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia","volume":"35","author":"Tadmor","year":"2021","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021011568","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia","volume":"137","author":"Herishanu","year":"2021","journal-title":"Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04866-z","article-title":"Definition of factors associated with negative antibody response after COVID-19 vaccination in patients with hematological diseases","volume":"101","author":"Rotterdam","year":"2022","journal-title":"Ann Hematol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.269878","article-title":"Immunologic characterization of COVID-19 patients with hematological cancer","volume":"106","author":"Maia","year":"2020","journal-title":"Haematologica"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1016\/j.immuni.2021.05.010","article-title":"Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune pathology distinguish severe COVID-19 from mild disease","volume":"54","author":"Bergamaschi","year":"2021","journal-title":"Immunity"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-022-00809-0","article-title":"Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab","volume":"23","author":"Bacova","year":"2023","journal-title":"Clin Exp Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-023-01359-1","article-title":"Fc-\u03b3R-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2","volume":"8","author":"Mackin","year":"2023","journal-title":"Nat Microbiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1159\/000534540","article-title":"COVID-19 in patients with chronic lymphocytic leukemia: what have we learned","volume":"147","author":"Harel","year":"2024","journal-title":"Acta Haematol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-021-00274-w","article-title":"Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study","volume":"2","author":"Fendler","year":"2021","journal-title":"Nat Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.3390\/biomedicines11092418","article-title":"Specific cellular and humoral response after the third dose of anti-SARS-coV-2 RNA vaccine in patients with immune-mediated rheumatic diseases on immunosuppressive therapy","volume":"11","author":"Mohamed Mohamed","year":"2023","journal-title":"Biomedicines"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.975980","article-title":"Evidence of exhausted lymphocytes after the third anti-SARS-CoV-2 vaccine dose in cancer patients","volume":"12","author":"Benitez Fuentes","year":"2022","journal-title":"Front Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"877","DOI":"10.3390\/vaccines12080877","article-title":"Vaccination with tozimameran induces T-cell activation, but not senescent or exhaustive alterations, in kidney transplant recipients","volume":"12","author":"Stai","year":"2024","journal-title":"Vaccines"},{"key":"B38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/ejh.v113.1","article-title":"Cross-talk between leukemic and immune cells at the tumor microenvironment in chronic lymphocytic leukemia: An update review","volume":"113","author":"Taghiloo","year":"2024","journal-title":"Eur J Haematol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e247090","DOI":"10.6004\/jnccn.2024.7090","article-title":"Immune dysfunction and consequences in chronic lymphocytic leukemia","volume":"23","author":"Narkhede","year":"2025","journal-title":"J Natl Compr. Canc. Netw"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2024.01.003","article-title":"Vaccinations in patients with chronic lymphocytic leukemia","volume":"61","author":"Francis","year":"2024","journal-title":"Semin Hematol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.3390\/cancers16213574","article-title":"The immunomodulatory mechanisms of BTK inhibition in CLL and beyond","volume":"16","author":"Jiang","year":"2024","journal-title":"Cancers"}],"updated-by":[{"DOI":"10.3389\/fimmu.2025.1706723","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1571680\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T15:36:27Z","timestamp":1758296187000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1571680\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":41,"alternative-id":["10.3389\/fimmu.2025.1571680"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1571680","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"article-number":"1571680"}}